Published in J Korean Med Sci on August 01, 2004
Hepatitis B virus infection. N Engl J Med (1997) 14.50
A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med (1998) 9.03
Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med (2003) 5.97
Chronic hepatitis B. Hepatology (2001) 5.90
Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med (1999) 5.32
Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology (1998) 4.14
Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med (2003) 4.12
Histological outcome during long-term lamivudine therapy. Gastroenterology (2003) 3.88
Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology (2000) 3.58
Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med (1993) 3.53
Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology (1999) 3.11
Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology (2004) 2.97
Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology (2003) 2.80
Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology (2001) 2.72
Chronic hepatitis B: update of recommendations. Hepatology (2004) 2.69
Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology (2004) 2.44
Hepatitis B e antigen-negative chronic hepatitis B. Hepatology (2001) 2.29
Adefovir nephrotoxicity: possible role of mitochondrial DNA depletion. Hum Pathol (2001) 2.20
Epidemiological findings of hepatitis B infection based on 1998 National Health and Nutrition Survey in Korea. J Korean Med Sci (2002) 2.03
Hepatitis B: an important public health issue. J Med Virol (2000) 1.81
Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology (2000) 1.78
Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology (2003) 1.78
EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002: Geneva, Switzerland. Consensus statement (short version). J Hepatol (2003) 1.74
Consensus statements on the prevention and management of hepatitis B and hepatitis C in the Asia-Pacific region. Core Working Party for Asia-Pacific Consensus on Hepatitis B and C. J Gastroenterol Hepatol (2000) 1.64
No benefit to continue lamivudine therapy after emergence of YMDD mutations. Antivir Ther (2004) 1.62
Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology (2002) 1.60
Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology (2000) 1.55
Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology (2003) 1.48
Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology (2001) 1.38
Asian-Pacific consensus statement on the management of chronic hepatitis B: an update. J Gastroenterol Hepatol (2003) 1.34
YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitro full-length viral DNA transfection. Hepatology (1999) 1.26
Long-term outcome of chronic type B hepatitis in patients who acquire hepatitis B virus infection in childhood. Gastroenterology (1990) 1.23
Diagnosis and management of pre-core mutant chronic hepatitis B. J Viral Hepat (2001) 1.10
Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. Gastroenterology (1995) 1.07
Natural history of hepatitis B virus infection in children. J Gastroenterol Hepatol (2000) 1.05
Long-term additional lamivudine therapy enhances durability of lamivudine-induced HBeAg loss: a prospective study. J Hepatol (2003) 1.03
Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconversion. J Viral Hepat (2002) 1.00
Treatment of HBeAg-negative chronic hepatitis B. Semin Liver Dis (2003) 0.97
Seroepidemiology of HBV infection in South Korea, 1995 through 1999. Korean J Intern Med (2001) 0.90
Interferon monotherapy in chronic hepatitis B. J Gastroenterol Hepatol (2000) 0.90
Clinical course after stopping lamivudine in chronic hepatitis B patients with lamivudine-resistant mutants. Aliment Pharmacol Ther (2004) 0.80
A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int (2011) 3.69
Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer (2011) 2.81
Estimation of the healthy upper limits for serum alanine aminotransferase in Asian populations with normal liver histology. Hepatology (2010) 2.38
Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol (2009) 2.21
Reappraisal of repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein invasion. J Gastroenterol Hepatol (2009) 2.16
Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology (2006) 1.93
Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the portal vein: long-term patient outcomes. Int J Radiat Oncol Biol Phys (2011) 1.78
Noninvasive diagnostic criteria for hepatocellular carcinoma in hepatic masses >2 cm in a hepatitis B virus-endemic area. Liver Int (2011) 1.77
Aberrant epigenetic modifications in hepatocarcinogenesis induced by hepatitis B virus X protein. Gastroenterology (2007) 1.68
Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone. Hepatology (2009) 1.66
Non-invasive assessment of hepatic steatosis: prospective comparison of the accuracy of imaging examinations. J Hepatol (2010) 1.61
Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function. Cancer Chemother Pharmacol (2011) 1.61
A nationwide seroepidemiology of hepatitis C virus infection in South Korea. Liver Int (2013) 1.57
Recurrences of hepatocellular carcinoma following initial remission by transcatheter arterial chemoembolization. J Gastroenterol Hepatol (2002) 1.37
Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models. Radiology (2011) 1.36
Clinical outcome of 251 patients with extrahepatic metastasis at initial diagnosis of hepatocellular carcinoma: does transarterial chemoembolization improve survival in these patients? J Gastroenterol Hepatol (2011) 1.23
Suppressive effects of entecavir on hepatitis B virus and hepatocellular carcinoma. J Gastroenterol Hepatol (2011) 1.12
Recent increase in antibiotic-resistant microorganisms in patients with spontaneous bacterial peritonitis adversely affects the clinical outcome in Korea. J Gastroenterol Hepatol (2003) 1.12
Transforming growth factor-beta1 as a useful serologic marker of small hepatocellular carcinoma. Cancer (2002) 1.09
Adiponectin and adiponectin receptor in relation to colorectal cancer progression. Int J Cancer (2010) 1.08
Surgical treatments and prognoses of patients with combined hepatocellular carcinoma and cholangiocarcinoma. Ann Surg Oncol (2009) 1.05
Sorafenib for recurrent hepatocellular carcinoma after liver transplantation. Jpn J Clin Oncol (2010) 1.05
Combination of transarterial chemoembolization and three-dimensional conformal radiotherapy for hepatocellular carcinoma with inferior vena cava tumor thrombus. Int J Radiat Oncol Biol Phys (2009) 1.04
Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir. J Hepatol (2010) 1.04
Long-term additional lamivudine therapy enhances durability of lamivudine-induced HBeAg loss: a prospective study. J Hepatol (2003) 1.03
Emergency adult-to-adult living-donor liver transplantation for acute liver failure in a hepatitis B virus endemic area. Hepatology (2010) 0.99
Randomized trial of entecavir plus adefovir in patients with lamivudine-resistant chronic hepatitis B who show suboptimal response to lamivudine plus adefovir. Antimicrob Agents Chemother (2012) 0.97
Sorafenib dose escalation in the treatment of advanced hepatocellular carcinoma. Oncology (2012) 0.96
Entecavir plus adefovir combination treatment for chronic hepatitis B patients after failure of nucleoside/nucleotide analogues. Antivir Ther (2012) 0.95
[A case of acute hepatitis a complicated by Guillain-Barré syndrome]. Korean J Hepatol (2007) 0.94
Lens culinaris agglutinin-reactive alpha-fetoprotein as a prognostic marker in patients with hepatocellular carcinoma undergoing transcatheter arterial chemoembolization. J Clin Gastroenterol (2002) 0.93
Complete necrosis after transarterial chemoembolization could predict prolonged survival in patients with recurrent intrahepatic hepatocellular carcinoma after curative resection. Ann Surg Oncol (2009) 0.91
Role of additional angiography and chemoembolization in patients with hepatocellular carcinoma who achieved complete necrosis following transarterial chemoembolization. J Gastroenterol Hepatol (2004) 0.91
Preoperative portal vein embolization and surgical resection in patients with hepatocellular carcinoma and small future liver remnant volume: comparison with transarterial chemoembolization. Ann Surg Oncol (2007) 0.90
Focal nodular hyperplasia or focal nodular hyperplasia-like lesions of the liver: a special emphasis on diagnosis. J Gastroenterol Hepatol (2011) 0.89
Four cases of hepatitis B virus-related fibrosing cholestatic hepatitis treated with lamivudine. J Gastroenterol Hepatol (2002) 0.88
Hepatic myelopathy as a presenting neurological complication in patients with cirrhosis and spontaneous splenorenal shunt. Korean J Hepatol (2008) 0.88
Characteristic clinical features of hepatocellular carcinoma associated with Budd-Chiari syndrome: evidence of different carcinogenic process from hepatitis B virus-associated hepatocellular carcinoma. Eur J Gastroenterol Hepatol (2004) 0.88
Production of cellulosic ethanol in Saccharomyces cerevisiae heterologous expressing Clostridium thermocellum endoglucanase and Saccharomycopsis fibuligera beta-glucosidase genes. Mol Cells (2009) 0.88
[Nine cases of sporadic acute hepatitis E in Korea]. Korean J Hepatol (2006) 0.88
Applicability of the BCLC staging system to patients with hepatocellular carcinoma in Korea: analysis at a single center with a liver transplant center. Korean J Hepatol (2011) 0.87
The characteristics of bio-oil produced from the pyrolysis of three marine macroalgae. Bioresour Technol (2010) 0.86
[Clinical and microbiological characteristics of spontaneous bacterial peritonitis (SBP) in a recent five year period]. Taehan Kan Hakhoe Chi (2002) 0.86
Maximum number of target lesions required to measure responses to transarterial chemoembolization using the enhancement criteria in patients with intrahepatic hepatocellular carcinoma. J Hepatol (2011) 0.86
[Usefulness of reagent strips for the diagnosis of spontaneous bacterial peritonitis]. Korean J Hepatol (2005) 0.86
High effectiveness of peginterferon alfa-2a plus ribavirin therapy in Korean patients with chronic hepatitis C in clinical practice. Clin Mol Hepatol (2013) 0.85
Bio-oil production from fast pyrolysis of waste furniture sawdust in a fluidized bed. Bioresour Technol (2009) 0.84
Which patients with chronic hepatitis B are more likely to relapse after interferon alpha-induced hepatitis B e antigen loss in Korea? J Clin Gastroenterol (2004) 0.84
rtL180M mutation of hepatitis B virus is closely associated with frequent virological resistance to adefovir dipivoxil therapy. J Gastroenterol Hepatol (2012) 0.84
Precore stop codon mutation of hepatitis B virus is associated with low breakthrough rate following long-term lamivudine therapy. J Gastroenterol Hepatol (2005) 0.83
Production of minicellulosomes from Clostridium cellulovorans for the fermentation of cellulosic ethanol using engineered recombinant Saccharomyces cerevisiae. FEMS Microbiol Lett (2010) 0.83
Combination of alpha-interferon with lamivudine reduces viral breakthrough during long-term therapy. J Gastroenterol Hepatol (2004) 0.81
[Clinical features of fulminant hepatic failure in a tertiary hospital with a liver transplant center in Korea]. Korean J Hepatol (2006) 0.80
Direct detection of lamivudine-resistant hepatitis B virus mutants by a multiplex PCR using dual-priming oligonucleotide primers. J Virol Methods (2008) 0.80
Susceptibility to type 1 autoimmune hepatitis is associated with shared amino acid sequences at positions 70-74 of the HLA-DRB1 molecule. J Hepatol (2007) 0.80
Current approaches for treating chronic hepatitis B: when to start, what to start with, and when to stop. Hepatol Int (2008) 0.79
Prognostic value of serum osteopontin in hepatocellular carcinoma patients treated with transarterial chemoembolization. Korean J Hepatol (2009) 0.78
Hepatitis B virus with the rtL80V/I mutation is associated with a poor response to adefovir dipivoxil therapy. Liver Int (2009) 0.78
Cellulose pretreatment with 1-n-butyl-3-methylimidazolium chloride for solid acid-catalyzed hydrolysis. Bioresour Technol (2010) 0.78
Cholestyramine resin for erythropoietic protoporphyria with severe hepatic disease: a case report. Korean J Hepatol (2010) 0.78
Clinical course of chronic hepatitis B patients who were off-treated after lamivudine treatment: analysis of 138 consecutive patients. Virol J (2012) 0.77
[Therapeutic efficacy of lamivudine in patients with hepatitis B virus-related decompensated cirrhosis in Korea]. Taehan Kan Hakhoe Chi (2002) 0.77
[Therapeutic efficacy of transjugular intrahepatic portosystemic shunt on bleeding gastric varices]. Taehan Kan Hakhoe Chi (2002) 0.77
Randomized trial of the virologic response during up to two years of entecavir-adefovir combination therapy in multiple-drug-refractory chronic hepatitis B virus patients. Antimicrob Agents Chemother (2013) 0.76
Neural cadherin overexpression is a predictive marker for early postoperative recurrence in hepatocellular carcinoma patients. J Gastroenterol Hepatol (2007) 0.76
Could HBx protein expression affect signal pathway inhibition by gefitinib or selumetinib, a MEK inhibitor, in hepatocellular carcinoma cell lines? J Korean Med Sci (2011) 0.75
Individualization of interferon therapy using serum hepatitis B virus DNA to reduce viral relapse in patients with chronic hepatitis B: a randomized controlled trial. Eur J Gastroenterol Hepatol (2003) 0.75
Biochemical Rather than Virologic Response to Interferon Therapy may be More Closely Associated with Decrease of Hepatocellular Carcinoma Incidence in Patients with Chronic Hepatitis B. Gut Liver (2007) 0.75
Osler-Weber-Rendu disease presenting with hepatocellular carcinoma: radiologic and genetic findings. Korean J Hepatol (2011) 0.75
Catalytic upgrading of xylan over mesoporous Y catalyst. J Nanosci Nanotechnol (2014) 0.75
In situ catalytic pyrolysis of miscanthus over modified SBA-15 catalysts using Py-GC/MS. J Nanosci Nanotechnol (2014) 0.75
[Validation of international autoimmune hepatitis group scoring system for diagnosis of type 1 autoimmune hepatitis in Korea]. Taehan Kan Hakhoe Chi (2002) 0.75
Catalytic Depolymerization of Alkali Lignin Using Supported Pt Nanoparticle Catalysts. J Nanosci Nanotechnol (2016) 0.75
Lamivudine therapy for decompensated liver cirrhosis related to hepatitis B virus infection. Intervirology (2003) 0.75
Antifibrogenic effects of tamoxifen in a rat model of periportal hepatic fibrosis. Liver Int (2008) 0.75
[The effects of tamoxifen on human hepatocellular carcinoma cell proliferation and transforming growth factor-beta1 expression]. Taehan Kan Hakhoe Chi (2003) 0.75
Application of mesoporous Al-MCM-48 material to the conversion of lignin. J Nanosci Nanotechnol (2014) 0.75
Catalytic Reforming of Lignin-Derived Bio-Oil Over a Nanoporous Molecular Sieve Silicoaluminophosphate-11. J Nanosci Nanotechnol (2016) 0.75
Highly Dispersed Pt Nanoparticles for the Production of Aromatic Hydrocarbons by the Catalytic Degrading of Alkali Lignin. J Nanosci Nanotechnol (2016) 0.75
Clinical usefulness of endoscopic palliation in patients with biliary obstruction caused by hepatocellular carcinoma. Digestion (2013) 0.75
Catalytic fast pyrolysis of lignin over mesoporous Y zeolite using Py-GC/MS. J Nanosci Nanotechnol (2013) 0.75
[Mutations within the interferon sensitivity determining region in Korean patients infected with hepatitis C virus genotype 1b]. Korean J Hepatol (2010) 0.75
The stability of platinum-carbon aerogel catalysts upon repeated potential cycles. ChemSusChem (2009) 0.75